Avsnitt
-
One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead for the market. Giving all of them hope were technological breakthroughs such as artificial intelligence, game changing weight loss drugs, the surging fascination with ADCs and hope for lower interest rates. But uncertainty looms about the upcoming general election in the U.S. and ground-shifting gene therapies. In a preview of the annual Biotech Showcase conference, an investor conference for private and micro- to mid-cap biotech companies Jan. 8-10 in San Francisco, BioWorld spoke with Dave Bearss, CEO of Halia Therapeutics Inc., Vimal Mehta, CEO of Bioxcel Therapeutics Inc., Paul Lammers, CEO at Triumvira Immunologics Inc., Chris Pirie, COO of HDT Bio Corp., Thijs Spoor, CEO of Perspective Therapeutics Inc. and Shelley Hartman, CEO of Aegle Therapeutics Corp. They offered insights brought about by years of hard-won experience.
-
Google’s Scott Penberthy joins the podcast for a visionary discussion that scans the horizon for startling changes artificial intelligence will bring to drug development in the relatively near future. Among the gems and eyebrow raisers is talk of dramatic reductions in the time it takes to identify the right molecule for development and how digital clinical trials in the not-too-distant future will substantially shrink study times. This episode also provides a preview of the annual Biofuture conference. Each year, a group of trailblazers, disruptors and forward-thinking executives converge to evaluate and forecast the future of health care. This year, BioWorld is a gold sponsor of the Oct. 4-6 event in New York. If you attend, you'll have the chance to hear panels and join workshops and fireside chats with key opinion leaders like Penberthy.
-
Saknas det avsnitt?
-
Guests Karen Carey, BioWorld’s managing editor, and Mike Ward, Clarivate’s global head of Life Sciences and Healthcare Thought Leadership, discuss the deals, financing and M&A landscape for the first half of 2023 and how U.K. biopharmas are faring post Brexit.
-
Guests BioWorld Regulatory Editor Mari Serebrov and Tom Newcomer, Samsung Bioepis vice president and head of U.S. market access, discuss the launch of biosimilars that are taking on a blockbuster.
-
Brad Holden, CEO of Resilient Lifescience, explains how the device works for overdoses as well as other potential applications for this new technology.
-
BioWorld Staff Writer Tamra Sami talks about the science behind radiopharmaceuticals, the supply chain vulnerabilities, the regulatory landscape, the patient journey and therapies in the pipeline.
Hosted on Acast. See acast.com/privacy for more information.
-
Guests Karen Zaderej, CEO of Axogen Inc., Sean Bohen, CEO of Olema Oncology Inc., Rob Ross, the CEO of Surface Oncology Inc., and Rob Etherington, the CEO of Clene Nanomedicine Inc., speak about adapting their companies to the market’s new realities.
Hosted on Acast. See acast.com/privacy for more information.
-
BioWorld Senior Analyst Karen Carey chats about the collision of a volatile economic climate and big biopharma deals.
Hosted on Acast. See acast.com/privacy for more information.
-
Extending the human lifespan, a BioWorld special report, examines the companies developing “Fountain of Youth” drugs. In this episode, the writers discuss this scientific holy grail.
Hosted on Acast. See acast.com/privacy for more information.
-
BioWorld Senior Analyst Karen Carey explores the newest data and where it is leading.
Hosted on Acast. See acast.com/privacy for more information.
-
Infection control expert William Schaffner of the Vanderbilt University School of Medicine joins to discuss the CDC’s Advisory Committee on Immunization Practices and how COVID-19 put the committee’s schedule into overdrive.
-
Senior Science Editor Anette Breindl goes in depth about how long COVID-19 emerged and is being defined.
Hosted on Acast. See acast.com/privacy for more information.
-
Guests Ryan Abbott, a professor of law and medicine, as well as the leader of the Artificial Inventor Project, and Jim Belfiore, senior vice president of innovation at Clarivate plc, have a discussion about the brave new world AI is creating.
Hosted on Acast. See acast.com/privacy for more information.
-
A conversation with Kleanthis Xanthopoulos, a co-founder and executive chairman of Shoreline Biosciences, and Joe Hernandez, CEO and executive chairman of Blue Water Vaccines, who have founded or led eight health care and pharmaceuticals companies.
Hosted on Acast. See acast.com/privacy for more information.
-
Insights into the controversial drug come from guests Michael Agadjanyan, president of Nuravax Inc., which is developing antibodies for preventing Alzheimer’s and Parkinson’s diseases, along with Robert Glanzman, chief medical officer of Clene Nanomedicine Inc.
Hosted on Acast. See acast.com/privacy for more information.
- Visa fler